Articles > Popular publications > PR Newswire press releases > July-September 1998 > Wednesday, July 1

Article: PathoGenesis Corp. Receives U.S. Patent for Aerosolized Drug Candidate

Article from:
PR Newswire
Article date:
July 1, 1998
Copyright 
 
  Second Entry in Portfolio to Treat Chronic Lung Infections

SEATTLE, July 1 /PRNewswire/ -- PathoGenesis Corp. (Nasdaq: PGNS) today announced it has been granted a U.S. patent for PA-1420 (polymyxin E1*), a broad-spectrum gram-negative aerosolized antibiotic now in preclinical development. PA-1420 is the second entry in the company's planned portfolio of aerosolized antibiotics to treat a number of chronic lung infections, including those common in cystic fibrosis, bronchiectasis, ventilator- dependent and immunocompromised patients.

"PA-1420 is a potent antibiotic active against difficult-to-treat pseudomonal lung infections. We expect it ...

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Article: PathoGenesis Corp. Receives $1.5 Million Grant to ...
PR Newswire;  August 23, 1999 ;     700+ words ... ... PRNewswire/ -- PathoGenesis Corp. (Nasdaq ... treat serious lung infections, particularly ... devastating CF lung infections." The Cystic ... Seattle-based PathoGenesis Corp. develops ... serious chronic lung infections, including ...

Article: PathoGenesis Corp. Receives European Patent for ...
PR Newswire;  May 31, 2000 ;     700+ words ... ... difficult-to-treat lung infections. Next month, we expect ... used in Europe to treat lung infections." Seattle-based PathoGenesis Corp. develops and commercializes ... particularly serious lung infections, including those common ...

Article: Pathogenesis Corp. Previews Record Fourth Quarter ...
PR Newswire;  January 10, 2000 ;     700+ words ... ... 10 /PRNewswire/ -- PathoGenesis Corp. (Nasdaq: PGNS) expects ... for tough-to-treat lung infections. It's an exciting time ... development. Seattle-based PathoGenesis Corp. develops and commercializes ... particularly serious lung infections, including those common ...

Article: PathoGenesis Corp. Begins Clinical Trial Of TOBI in ...
PR Newswire;  May 30, 2000 ;     700+ words ... ... May 30 /PRNewswire/ -- PathoGenesis Corp. (Nasdaq: PGNS) has ... Pseudomonas aeruginosa lung infections but who have not yet experienced ... patients. Seattle-based PathoGenesis Corp. develops and commercializes ... particularly serious lung infections. PathoGenesis' stock ...

Article: PathoGenesis Corp. Announces Further Expansion in ...
PR Newswire;  April 3, 2000 ;     700+ words ... ... April 3 /PRNewswire/ -- PathoGenesis Corp. (Nasdaq: PGNS) today ... Netherlands. Seattle-based PathoGenesis Corp. develops and commercializes ... diseases -- particularly serious lung infections, including those common in ...

Article: PathoGenesis Corp. Reports Strong Fourth Quarter ...
PR Newswire;  January 24, 2000 ;     700+ words ... ... Jan. 24 /PRNewswire/-- PathoGenesis Corp. (Nasdaq: PGNS) today ... of 1998. Seattle-based PathoGenesis Corp. develops and commercializes ... diseases -- particularly serious lung infections, including those common in ...

Article: PathoGenesis Corp. Estimates Record Second Quarter ...
PR Newswire;  July 5, 2000 ;     700+ words ... ... July 5 /PRNewswire/ -- PathoGenesis Corp. (Nasdaq: PGNS) today ... strains. Seattle-based PathoGenesis Corp. develops and commercializes ... diseases -- particularly serious lung infections, including those common in ...

Article: PathoGenesis Corp. Reports First Quarter 2000 ...
PR Newswire;  April 18, 2000 ;     700+ words ... ... April 18 /PRNewswire/ -- PathoGenesis Corp. (Nasdaq: PGNS) today ... for TOBI." Seattle-based PathoGenesis Corp. develops and commercializes ... diseases -- particularly serious lung infections, including those common in ...

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!

Find articles, research, and archives